Treatment of Hypothalamic Obesity With GLP-1 Analogs

Overview

Journal J Endocr Soc

Specialty Endocrinology

Date 2024 Dec 20

PMID 39703362

Authors

Paul Dimitri

Christian L Roth

Affiliations

Soon will be listed here.

Abstract

Introduction: Congenital and acquired damage to hypothalamic nuclei or neuronal circuits controlling satiety and energy expenditure results in hypothalamic obesity (HO). To date, successful weight loss and satiety has only been achieved in a limited number of affected patients across multiple drug trials. Glucagon-like peptide-1 (GLP-1) acts via central pathways that are independent from the hypothalamus to induce satiety. GLP-1 receptor agonists (GLP-1RAs) may provide an alternative approach to treating HO.

Methods: We performed a comprehensive search in Medline, Google Scholar, and clinical trials registries (ClinicalTrials.gov; clinicaltrialsregister.eur). This nonsystematic literature review was conducted to identify scientific papers published from January 2005 to February 2024 using the Pubmed and Embase databases. Key words used were GLP-1, GLP-1RA, hypothalamic obesity, suprasellar tumor, and craniopharyngioma.

Results: Our search identified 7 case studies, 5 case series, and 2 published clinical trials relating to the use of GLP-1RAs in HO. All case studies demonstrated weight loss and improved metabolic function. In contrast, results from case series were variable, with some showing no weight loss and others demonstrating moderate to significant weight loss and improved metabolic parameters. In the ECHO clinical trial, nearly half the subjects randomized to weekly exenatide showed reduced body mass index (BMI). Paradoxically, BMI reduction was greater in patients with more extensive hypothalamic injuries.

Conclusion: GLP-1RAs potentially offer a new approach to treating HO. There is a need to stratify patients who are more likely to respond. Further randomized controlled trials are required to determine their efficacy either in isolation or combined with other therapies.

References

Abuzzahab M, Roth C, Shoemaker A . Hypothalamic Obesity: Prologue and Promise. Horm Res Paediatr. 2019; 91(2):128-136. DOI: 10.1159/000496564. View

Sciacovelli C, Moschione G, Garelli S, Pagotto U . Semaglutide for Treating Obesity Induced by Craniopharyngioma Resection: A Successful Case Study. JCEM Case Rep. 2023; 1(4):luad074. PMC: 10580492. DOI: 10.1210/jcemcr/luad074. View

Sainsbury A, Cooney G, Herzog H . Hypothalamic regulation of energy homeostasis. Best Pract Res Clin Endocrinol Metab. 2002; 16(4):623-37. DOI: 10.1053/beem.2002.0230. View

Ahmet A, Blaser S, Stephens D, Guger S, Rutkas J, Hamilton J . Weight gain in craniopharyngioma--a model for hypothalamic obesity. J Pediatr Endocrinol Metab. 2006; 19(2):121-7. DOI: 10.1515/jpem.2006.19.2.121. View

Clement K, van den Akker E, Argente J, Bahm A, Chung W, Connors H . Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020; 8(12):960-970. DOI: 10.1016/S2213-8587(20)30364-8. View

van Eyk H, Paiman E, Bizino M, IJzermans S, Kleiburg F, Boers T . Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2020; 30(4):616-624. DOI: 10.1016/j.numecd.2019.12.005. View

Collet T, Dubern B, Mokrosinski J, Connors H, Keogh J, Mendes de Oliveira E . Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017; 6(10):1321-1329. PMC: 5641599. DOI: 10.1016/j.molmet.2017.06.015. View

Hoffman H, De Silva M, Humphreys R, Drake J, Smith M, Blaser S . Aggressive surgical management of craniopharyngiomas in children. J Neurosurg. 1992; 76(1):47-52. DOI: 10.3171/jns.1992.76.1.0047. View

Roh E, Song D, Kim M . Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism. Exp Mol Med. 2016; 48:e216. PMC: 4892882. DOI: 10.1038/emm.2016.4. View

10.

Bojanowska E, Nowak A . Interactions between leptin and exendin-4, a glucagon-like peptide-1 agonist, in the regulation of food intake in the rat. J Physiol Pharmacol. 2007; 58(2):349-60. View

11.

Thondam S, Cuthbertson D, Aditya B, MacFarlane I, Wilding J, Daousi C . A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2012; 77(4):635-7. DOI: 10.1111/j.1365-2265.2012.04368.x. View

12.

Singh S, Chang H, Richards T, Weiner J, Clark J, Segal J . Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013; 173(7):534-9. DOI: 10.1001/jamainternmed.2013.2720. View

13.

ONeil P, Birkenfeld A, McGowan B, Mosenzon O, Pedersen S, Wharton S . Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018; 392(10148):637-649. DOI: 10.1016/S0140-6736(18)31773-2. View

14.

Melluso A, Secondulfo F, Capolongo G, Capasso G, Zacchia M . Bardet-Biedl Syndrome: Current Perspectives and Clinical Outlook. Ther Clin Risk Manag. 2023; 19:115-132. PMC: 9896974. DOI: 10.2147/TCRM.S338653. View

15.

Ahmann A, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I . Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2017; 41(2):258-266. DOI: 10.2337/dc17-0417. View

16.

Roth C, Eslamy H, Werny D, Elfers C, Shaffer M, Pihoker C . Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obesity (Silver Spring). 2015; 23(6):1226-33. PMC: 5029599. DOI: 10.1002/oby.21067. View

17.

Handelsman Y, Wyne K, Cannon A, Shannon M, Schneider D . Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. J Manag Care Spec Pharm. 2018; 24(9-a Suppl):S14-S29. PMC: 10408429. DOI: 10.18553/jmcp.2018.24.9-a.s14. View

18.

Tapia-Arancibia L, Rage F, Givalois L, Arancibia S . Physiology of BDNF: focus on hypothalamic function. Front Neuroendocrinol. 2004; 25(2):77-107. DOI: 10.1016/j.yfrne.2004.04.001. View

19.

Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R . Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023; 389(10):877-888. DOI: 10.1056/NEJMoa2302392. View

20.

Bretault M, Carette C, Zaharia R, Vychnevskaia K, Bouillot J, Czernichow S . Liraglutide 3mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma. Diabetes Metab. 2019; 46(6):514-515. DOI: 10.1016/j.diabet.2019.07.004. View